Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy

Table 4 Correlation between metabolic, and histopathologic response.

Response	Histopathologic responders *	Histopathologic non-responders	P-value^†
Metabolic responders
Responders	12 (32.4%)	25 (67.6%)	0.002
Non-responders	2 (4.9%)	39 (95.1%)
	For histopathologic responders	For histopathologic nonresponder
Sensitivity	85.7% (12/14)	60.9% (39/64)
Specificity	60.9% (39/64)	85.7% (12/14)
Positive predictive value	32.4% (12/37)	95.1% (39/41)
Negative predictive value	95.1% (39/41)	32.4% (12/37)

* Pathologic complete response or minimal residual disease were regarded as histopathologic responders, Gross residual disease were regarded as histopathologic non-responders.
^† P-value based on the Fisher's exact test

ISSN: 1471-2407